Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Withdrawal From Diabetes Drugs Research May Help Glenmark (India) "

This article was originally published in PharmAsia News

Executive Summary

Glenmark Pharmaceuticals is expected to benefit from a recent announcement by Merck KGaA that the international drug-maker is stopping all research and development for diabetes drugs. Currently, Merck and the India-based Glenmark have a E190 million licensing deal for Glenmark's experimental diabetes treatment, GRC 8200. The deal would have given Merck the right to market the drug in Japan, Europe, and the United States while Glenmark retained the Indian rights. Merck already paid Glenmark E25 million for the drug when it was in initial clinical trials, last year. Since that time, GRC 8200 has progressed into later-stage human testing, making it much more attractive to investors. Now, with the return of the licensing rights, Glenmark may be able to sell the molecule for a higher price to a third-party. Despite Merck's withdrawal, development of the drug is expected to continue on schedule. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065732

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel